MOLOGEN AG: U.S. patent for lead product MGN1703 in combination with chemotherapy announced

MOLOGEN AG announces that the United States Patent and Trademark Office (PTO) has declared that it will grant a patent (Notice of Allowance) for the combined use of the lead product, immunotherapy MGN1703, with a chemotherapeutic agent.

MGN1703 is currently being tested in a phase III IMPALA pivotal study, both as a monotherapy and in combination with chemotherapy. The patent will be granted for the USA and would, in the event of market approval there, cover the dosing regimen for MGN1703 in combination with chemotherapy. In addition, the patent will last probably several years longer than the initial patent for MGN1703 (substance patent) and would therefore permit a longer exclusive commercialization than the initial patent. 


Claudia Nickolaus

Head of Investor Relations & Corporate Communications

Tel: +49 - 30 - 84 17 88 – 38

Fax: +49 - 30 - 84 17 88 - 50

Note about risk for future predictions

Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

Strategy program "NEXT LEVEL"

Dr. Mariola Söhngen CEO MOLOGEN AG